ArticleAmerican journal of translational research2018
LincRNA-p21 sponges miR-18b to promote the progression of diabetic nephropathy.
Article in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- LincRNA-p21/AIF-1/CMPK2/NLRP3 pathway promoted inflammation, autophagy and apoptosis of human tubular epithelial cell induced by urate via exosomes.Scientific reports · 2024Article
- Tubule-specific deletion ofMolecular therapy. Nucleic acids · 2021Article
- KCNQ1OT1/miR-18b/HMGA2 axis regulates high glucose-induced proliferation, oxidative stress, and extracellular matrix accumulation in mesangial cells.Molecular and cellular biochemistry · 2021Article
- An update on long intergenic noncoding RNA p21: a regulatory molecule with various significant functions in cancer.Cell & bioscience · 2020Review
- LncRNA KCNQ1OT1 affects cell proliferation, apoptosis and fibrosis through regulating miR-18b-5p/SORBS2 axis and NF-ĸB pathway in diabetic nephropathy.Diabetology & metabolic syndrome · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Little is known about the role of lincRNA-p21 in the development of diabetic nephropathy. The aim of the present study was to investigate the level of lincRNA-p21 in diabetic nephropathy, and explore its underlying mechanism. The current study revealed that down-regulation of lincRNA-p21 could alleviate pathological changes of diabetic nephropathy in mice. LincRNA-p21 expression was significantly up-regulated in MMCs under high glucose condition in
Indexed as
Identifiers
29887961PMC5992561W3023795406What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.